Anti-tumor drug classification and management system

Legal analysis: In order to standardize the rational application of antitumor drugs, to ensure the safety of patients, according to the Ministry of Health "clinical application of antitumor drugs guiding principles" antitumor drugs, antitumor drugs, such as the mechanism of action, clinical efficacy, adverse drug reactions and drug prices, antitumor drugs are divided into one, two, three levels, and to develop a Anti-tumor drugs classification management system

I. Principles of classification

1. Class I drugs: common drugs, including general chemotherapeutic drugs and endocrine therapeutic drugs, that have been clinically proven to be safe in long-term application, with mild adverse reactions, simple medication methods, and inexpensive prices.

2, the second level of drugs: compared with the first level of drugs, in terms of safety, price has certain limitations, there are certain adverse reactions, and the use of the process is more complex or have special requirements of the drug.

3, tertiary drugs: there are greater limitations in safety, adverse reactions, complexity of the process of using drugs, higher prices, and clinical use of drugs need special application of drugs, generally for the third-line program drugs.

II. Grading management:

1. Clinicians choose antitumor drugs according to diagnosis, patient staging and previous treatment. According to the principle of antitumor drug classification, the first-class drugs are used by residents and above, the second-class drugs are used by attending physicians and above, and the third-class drugs are used by deputy chief physicians and above. Each department will specify the level of antitumor drugs that each clinician can use according to the above principles.

2. The development or replacement of antitumor treatment plan must be determined by the attending physician or above, and reflected in the content of the medical record.

3, on the tumor chemotherapeutic drugs of the super routine, super dose, new route of medication plan, should be determined by the clinician (deputy chief physician and above) and clinical pharmacists through case discussion.

4, standardized and correct use of oncology chemotherapeutic drugs, the possible adverse reactions to start the emergency response plan, the pharmacy department to provide the necessary information support.

Legal basis: "Measures for the Administration of Clinical Application of Anti-tumor Drugs" Article 6 The clinical application of anti-tumor drugs is subject to hierarchical management. According to safety, accessibility, economy and other factors, antitumor drugs are divided into restricted-use level and general-use level. Specific standards are as follows:

(1) restricted-use antineoplastic drugs refer to antineoplastic drugs with one of the following characteristics:

1. antineoplastic drugs with high toxicity and side effects, which are included in the management of toxic medicines, with strict indications and contraindications, and have to be used by medical personnel with rich clinical experience, and the improper use of which may cause serious damages to the human body;

2. New antitumor drugs with short time on the market and little experience in the use of drugs;

3. Antitumor drugs with high price and heavy economic burden.

(2) General-use-grade antitumor drugs refer to antitumor drugs other than restricted-use-grade antitumor drugs.

Anti-tumor drug classification and management catalog is formulated by medical institutions and dynamically adjusted. Local health administration departments guide the formulation and adjustment of the graded management catalog of antineoplastic drugs.

The principles of grading are as follows: Class I drugs: common drugs that have been clinically proven to be safe in long-term application, with mild adverse reactions, simple medication methods and low prices, including general chemotherapeutic drugs and endocrine therapeutic drugs. Second-class drugs: compared with the first-class drugs, there are certain limitations in terms of safety, price, and certain adverse reactions, and the use of the process is more complex or have special requirements of the drug. Tertiary drugs: there are greater limitations in safety, obvious adverse reactions, complexity of the medication process, higher prices, as well as clinical use of drugs require special application of the drug, generally for the third-line program drugs.